Sugi Predict

Sugi Predict / Compounds / SCHEMBL5887673

SCHEMBL5887673

SCHEMBL5887673

CC(=O)O[C@@H]1[C@H](OC(C)=O)C(C)(C)C[C@@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)[C@@](C)(CO)C5CC[C@@]4(C)[C@]3(C)CC[C@]21C

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 9/20 0.63
▸ F3 P13726 4/20 0.63
▸ USP2 O75604 1/20 0.63
▸ LMNA P02545 1/20 0.63
▸ CYP3A4 P08684 1/20 0.63
▸ USP7 Q93009 1/20 0.63
▸ SLCO1B3 Q9NPD5 1/20 0.63
▸ SLCO1B1 Q9Y6L6 1/20 0.63
▸ ALOX5 P09917 1/20 0.63
▸ CES2 O00748 1/20 0.57
▸ CES1 P23141 1/20 0.57
▸ EGFR P00533 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887594 0.95 PTPN1 (0.63) PTPN1F3USP2LMNACYP3A4
SCHEMBL5887960 0.88 ALOX5 (0.67) PTPN1F3USP2LMNACYP3A4
SCHEMBL5887703 0.86 ALOX5 (0.67) PTPN1F3USP2LMNACYP3A4
SCHEMBL5887733 0.86 ALOX5 (0.67) PTPN1F3USP2LMNACYP3A4
Soyasapogenol A SCHEMBL24626884 0.84 ALOX5 (0.73) PTPN1F3USP2LMNACYP3A4
Soyasapogenol A SCHEMBL6241027 0.84 ALOX5 (0.73) PTPN1F3USP2LMNACYP3A4
Soyasapogenol A SCHEMBL21886589 0.84 ALOX5 (0.73) PTPN1F3USP2LMNACYP3A4
Soyasapogenol A SCHEMBL5887575 0.84 ALOX5 (0.73) PTPN1F3USP2LMNACYP3A4
Soyasapogenol A SCHEMBL16431091 0.84 ALOX5 (0.73) PTPN1F3USP2LMNACYP3A4
Soyasapogenol A SCHEMBL828826 0.84 ALOX5 (0.73) PTPN1F3USP2LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7153979-B2 Triterpene derivatives and remedies for liver diseases MEIJI SEIKA KAISHA, LTD. (JP) 2006-12-26 — — US disclosed
US-20030195182-A1 Triterpene derivatives and remedies for liver diseases SASAKI KAZUE (JP) 2003-10-16 — — US disclosed
US-6593364-B2 Oxireno-, azetidino-, and methano- picene derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2003-07-15 — — US disclosed
US-20020016481-A1 Triterpene derivatives and remedies for liver diseases SASAKI KAZUE (JP) 2002-02-07 — — US disclosed
EP-0889051-B1 TRITERPENE DERIVATIVES AND REMEDIES FOR LIVER DISEASES MEIJI SEIKA CO (JP) 2001-08-08 — — EP disclosed
US-6201018-B1 EFFECTIVENESS MEIJI SEIKA KAISHA, LTD. (JP) 2001-03-13 — — US disclosed
EP-0889051-A1 TRITERPENE DERIVATIVES AND REMEDIES FOR LIVER DISEASES MEIJI SEIKA KABUSHIKI KAISHA (JP) 1999-01-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016481-A1 Triterpene derivatives and remedies for liver diseases NR1H3, NR1H2, OXER1 PTPN1 1660/4885F3 1203/4885USP2 4317/4885
US-20030195182-A1 Triterpene derivatives and remedies for liver diseases NR1H3, NR1H2, OXER1 PTPN1 1675/4885F3 1180/4885USP2 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.